HUTCHMED (China) Investor Relations Material
Latest events
H2 2024
HUTCHMED (China)
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from HUTCHMED (China) Limited
Access all reports
HUTCHMED Limited is a global biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company integrates innovative science and clinical expertise to develop a robust pipeline of therapies, leveraging its research and development capabilities in China and internationally. HUTCHMED markets its products in various regions and collaborates with global pharmaceutical partners for distribution and development. The company is headquartered in Hong Kong, China, and its shares are listed on the NASDAQ and the London Stock Exchange (LSE).
Key slides for HUTCHMED (China) Limited
H1 2024
HUTCHMED (China) Limited
R&D Update
HUTCHMED (China) Limited
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
HCM
Country
🇬🇧 United Kingdom